Compare SAH & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAH | ZLAB |
|---|---|---|
| Founded | 1997 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.4B |
| IPO Year | 1997 | 2017 |
| Metric | SAH | ZLAB |
|---|---|---|
| Price | $78.64 | $19.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $78.25 | $49.60 |
| AVG Volume (30 Days) | 192.7K | ★ 635.2K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.07% | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | ★ 1.79 | N/A |
| Revenue | ★ $9,951,630,000.00 | $460,156,000.00 |
| Revenue This Year | $4.61 | $9.75 |
| Revenue Next Year | $4.16 | $26.03 |
| P/E Ratio | $45.27 | ★ N/A |
| Revenue Growth | 0.86 | ★ 15.33 |
| 52 Week Low | $54.11 | $15.96 |
| 52 Week High | $89.38 | $44.34 |
| Indicator | SAH | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 64.10 | 42.01 |
| Support Level | $77.10 | $19.51 |
| Resistance Level | $81.51 | $19.64 |
| Average True Range (ATR) | 3.27 | 0.93 |
| MACD | 0.35 | -0.44 |
| Stochastic Oscillator | 64.62 | 25.76 |
Sonic Automotive is one of the largest auto dealership groups in the United States. The company has 111 franchised stores in 18 states, primarily in metropolitan areas in California, Texas, and the Southeast, plus 18 EchoPark used-vehicle stores in 10 states, 16 collision centers, and 14 powersports locations. The franchise stores derive revenue from new and used vehicles plus parts and collision repair, finance, insurance, and wholesale auctions. Luxury and import dealerships make up about 86% of franchise new-vehicle revenue, while Honda, BMW, Mercedes, and Toyota constitute about 56% of new-vehicle revenue. BMW is the largest brand at about 23%. 2025's revenue was $15.2 billion, with Texas and California comprising 51% of the total. EchoPark's portion was $2.1 billion.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.